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Management of Advanced Endodermal Sinus l\imor ofthe Ovary
with Preservation of Reproductive Function
Michael L. Hicks, MD,* Shari L. Maxwell, MD,* and Wooshin Kim, MD*

Endodermal sinus tumor ofthe ovary occurs primarily in children and young adults. This tumor is
classified as a germ ceU tumor which comprises approximately 5% of all ovarian tumors. In the
past, patients wdh this highly malignant tumor had low survival. However, wdh the evolution
of effective adjunctive chemotherapeutic regimens, specifically vincristine, actinomycin D, and
cyclophosphamide, survival rates have improved. In an attempt to continuously improve survival
rates, other combination chemotherapeutic regimens are currently under investigation.
Unlike epithelial ovarian malignancies, endodermal sinus tumor can be monitored by a specific
tumor marker, alpha-fetoprotein (AFP). Serum levels of AFP can be followed from the preoperative
period through the course of chemotherapy. When elevated, AFP has excellent predictability that
persistent disease is present. Because this disease presents primarily in young females, preservation
of reproductive function is of utmost importance. We report a case of advanced endodermal sinus
tumor which was managed with conservative surgery only, followed by radical combination
chemotherapy, resulting in preservation of normal reproductive function and total resolution of
disea.se documented by second-look laparotomy. (Henry Ford Hosp MedJ 1990:38:76-8}

E

ndodermal sinus tumor of the ovary is classified as an ovarian germ cett tumor. Germ cefi tumors comprise approximately 5% ofall malignant ovarian tumors. Endodermal sinus
tumors occur primarily in children and young adults and are
characterized by their highly malignant nature.
The tumor was inifiatty de.scribed by Schiller (1) to be of mesonephric origin but was tater shown by Teitum (2,3) to originate
from extraembryonal germ cells. Histologic sections demonstrate papillary projections with a peripheral lining of neoplastic
celts with associated blood vessels (Schiller-Duval body) (Fig
1).
In the past, earty treatment modalities were unsuccessful because of the aggressive nature of these tumors. The prognosis
was poor and survival rates low, ranging from 9% to 13% (4-6).
To improve survival rates, several therapeufic regimens have
been evaluated over the past decade and some have been incorporated in the management of patients with these tumors.
We report a case of advanced endodermal sinus tumor managed with conservative surgery followed by radical combination chemotherapy, resulting in preservation of normal reproductive function and total resolution of disease documented by
second-took laparotomy.

showed a 13 X 10 cm solid mass extending into the cul-de-sac. No ascites were noted.
Exploratory laparotomy was performed, and 1,200 mL of ascitic fluid was removed from the abdominal cavity. Inspection of the pelvis revealed a 20 X 20 cm mass which was noled to be posterior to the uterus
and extending into the cul-de-sac. The mass was contiguous with the
righl ovary and adherent to the sigmoid, colon, rectum, posterior uterine wall, and cecum. The left ovary and tube were normal. Intraabdominal biopsies sent for frozen section were consistent with ovarian malignancy. The patient underwent right salpingo-oophorectomy, omentectomy, lysis of adhesions, appendectomy, and paraaortic and pelvic
lymph node biopsies, but tumor debulking was suboptimal. Pathology
revealed endodermal sinus tumor with surgical staging consistent with
stage IIIC disease. Postoperative recovery was unremarkable and the
patient was discharged home on the fifth day.
Five days later, the patient was readmitted for initial chemotherapy
induction which consisted of bleomycin, 20 U/m^ intravenous weekly,
etoposide (VP-16), IOO mg/m^ intravenous daily for five days, and cisplatin, 20 •mglm- intravenous daily for five days (BEP regimen). All
agents were repeated weekly for nine weeks. Maintenance chemotherapy, given after BEP induction, consisted of vincristine, 1.5 mg/m(single dose not to exceed 2 mg) intravenous at two-week intervals for
a total of six doses, and actinomycin D, 350 mg/m^, and cyclophosphamide, 150 mglm-, infi-avenous daily for five days at four-week intervals
for a tolal of three doses. Except for mild gastrointestinal and mucocutaneous toxicity, the patient tolerated the chemotherapy well.

Case Report
An 18-year-old, gravida 4 para 1/0/3/1, female presented with abdominal pain of one-month duration associated wilh nausea and vomiting. Her medical history was unremarkable. Physical examination revealed a palpable 16 cm abdominal mass with associated tenderness in
both lower quadrants and voluntary guarding ihroughout the entire abdomen. Pelvic examination confirmed the mass to be centrally located,
extending inlo the cul-de-sac, and solid in nature. Ultrasound findings
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Fig lA—Schiller-Duval body, characteristic of endodermal sinus tumor.

The second-look laparotomy, performed after completion of the chemotherapy, was negative. The patient curtently has normal menses and
no clinical evidence of disease.

Fig IB—Hyaline globules (arrow), characteristic of endodermal sinus tumor.

Discussion
The most common clinical findings with endodermal sinus
tumor are abdominal pain, abdominal-pelvic mass, fever, and
occasional vaginal bleeding. Complaints of pain are usually of
less than one-week duration but can be acute in onset secondary
to rupture or torsion of the ovarian tumor. The median age at
presentation is approximately 19 years.
Intraoperative management principles are the same as with
epithelial ovarian tumors. The surgeon's goat is to achieve appropriate cytoreduction by removing the bulk of the tumor
mass and to stage the disease adequately. Appropriate staging
is accomplished by obtaining cytological washings ofthe peritoneal cavity, performing omentectomy, paraaortic and pelvic
lymph node biopsies, and a detailed evaluation of the liver,
diaphragmatic surface, and abdominal and pelvic peritoneum.
Cytoreduction is essential to maximize tumor response to chemotherapy, whereas surgical staging allows the clinician to
develop the prognosis,
tn the two largest series analyzing the management of endodermal sinus tumor, both Gershenson et al (5) and Kurman and
Nonis (6) showed that surgery atone was not sufficient in improving pafient survival. Reported mortality rates at 24 months
were 75% and 82%, respectivety. In an attempt to improve survival rates, radiation therapy was incorporated in the postoperative period but was shown to be ineffective with mortality rates
of 100% in both series. Not until the use of combination chemotherapy with vincristine, actinomycin D, and cyclophosphamide
(VAC) was there any significant impact on patient survival. In
these two series, the survival rate with VAC was 72% (5) and
75% (6) at 120 months.
Although the use of adjunctive chemotherapy with the VAC
regimen has been shown to improve survival, these rates were
demonstrated primarily in earlier stages ofthe disease process
(stages I and II). There have been reports of VAC failures in
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stages III and IV. This has stimulated the search for other management options in the treatment of advanced stages of endodermal sinus ovarian tumors. Altemafive management regimens
are cunently being investigated in phase It clinical trials. The
use of a different combination of chemotherapeutic agents has
been suggested. Because vinbtasrine, bleomycin, and cis-platinum (VBP) have been shown to be effecfive in the treatment of
testicular cancer (7), some propose that VBP may be more effective than VAC in advanced stages of endodermal sinus tumors
and in cases where VAC has failed (8). Whether VBP witl become the recommended first-line of chemotherapy or used for
treatment salvage only is sfill under investigation. VBP is far
more toxic than VAC, and cases of drug-related deaths from
VBP have been reported.
The use of induction chemotherapy prior to maintenance chemotherapy has also been recommended and was used in the
management of the present case. The purpose of this regimen is
to elicit a more effective response against endodermal sinus tumor but with tess toxicity. Etoposide (VP-16) is subsfituted for
vinblastine and has heen shown to reduce neurologic toxicity
without compromising efficacy.
Because the disease presents primarily in young females, another problem the clinician must address is preservation of
reproductive function. If the extent of disease appears to be
only stage 1 at the time of inifial laparotomy, unilateral salpingooophorectomy may be as effective as bilateral salpingo-oophorectomy with total abdominal hysterectomy (8). Stayton et al (8)
reported that 21 of 30 patients resumed normal menses and that
three patients became pregnant after VAC chemotherapy postoperatively. Gershenson et al (5) reported that after conservative
surgery and VAC chemotherapy three patients subsequently
had five normal pregnancies. With a more radical course of chemotherapy such as BEP induction followed by VAC in ad-
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Fig 2—Relationship hetween AFP levels (tumor markers) before, during, and after BEP induction and VAC chemotherapy.

vanced disease states, conservative surgery can be done, allowing reproductive function to continue without compromising
treatment.
The need for second-look laparotomy in patients with endodermal sinus tumor has not been formally established. These patients are followed during the postoperative and chemotherapeutic period by testing semm alpha-fetoprotein (AFP) levels.
In our case, serum AFP levels were followed postoperatively
and during the course of combination chemotherapy (Fig 2).
Several studies have demonstrated that patients with normal
AFP levels after chemotherapy had no evidence of persistent
disease at the time of second-look laparotomy (5,8,9). These
data suggest that normal semm AFP levels may indicate no need
for a second-look laparotomy. However, Curtain et al (10) recently reported two patients with normal semm AFP levels postchemotherapy who had residual tumor noted during secondlook laparotomy. Although there are only two reported cases of
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persistent disease following chemotherapy, there are some benefits of second-look laparotomy, including early detection of
subclinical or persistent disease and documentafion of complete
versus partial response postchemotherapy.
When preservation of reproductive function is a major concern, we recommend that endodermal sinus tumor of the ovary
be managed with conservative surgery followed by aggressive
chemotherapy. AFP serum levels should be followed throughout the course of treatment. With this type of management, fertility can be preserved, survival improved, and identification
of tumor response to treatment accurately monitored.
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